CORDIS
EU research results

CORDIS

English EN
Studying the role of Quiescent Cancer Stem Cells in GBM development using a novel in vivo cell cycle-based approach

Studying the role of Quiescent Cancer Stem Cells in GBM development using a novel in vivo cell cycle-based approach

Objective

Glioblastoma (GBM) is the most common and aggressive high-grade primary brain tumour in adults. More than 90% of the patients shows recurrence of the disease with a survival of 2 years despite a multitherapeutic approach consisting of a first surgical resection of the brain lesion followed by radio- and chemo-therapy. GBM patients die because of the cancer relapse that evolve becoming not sensitive to the classical therapies. A sub-population of quiescent/slow cycling cancer stem cells (CSCs) has been proposed to be the origin of the cancer relapse. The features and role of that specific population of CSCs within GBM is still not well characterised. The aim of the proposed project is to first clarify the cell cycle state of CSCs within GBM induced in mouse models in addition to their contribution and role in cancer development. To achieve this goal, I will use a cell cycle-based approach together GBM mouse models to: characterise the cell cycle state of CSCs within tumour (Aim 1); analyse the contribution of quiescent and proliferating CSCs during cancer development and their molecular features using a novel cell cycle-based lineage tracing approach (Aim 2); analyse the effect of selective ablation of each CSCs sub-subpopulation in cancer growth a novel cell cycle-based cellular ablation (Aim 3). Using a cell cycle point of view, the obtained results will be fundamental for the definition and the role of the different CSCs co-existing within glioma. In particular, the findings will open new avenue in the study of the role of quiescent or proliferating cells within GBM and give the possibility to others in the field for testing for example which cells contribute to cancer relapse after the initial tumour treatment (mass debulking and following radio- and chemo-therapy) or even design new drugs targeting specific CSC types.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA DEGLI STUDI DI TRENTO

Address

Via Calepina 14
38122 Trento

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 183 473,28

Project information

Grant agreement ID: 844677

Status

Grant agreement signed

  • Start date

    1 April 2020

  • End date

    31 March 2022

Funded under:

H2020-EU.1.3.2.

  • Overall budget:

    € 183 473,28

  • EU contribution

    € 183 473,28

Coordinated by:

UNIVERSITA DEGLI STUDI DI TRENTO

Italy